Skip to main
MDT

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 30%
Buy 40%
Hold 30%
Sell 0%
Strong Sell 0%

Bulls say

Medtronic is a profitable, innovative company with strong potential for growth due to its successful Symplicity Spyral product, separation of its Diabetes business, potential for expansion into new markets, and a promising pipeline of products. However, there are risks to watch out for, such as unsuccessful product launches and fluctuations in the economy and currency. Overall, the stock has a positive outlook, with a Buy rating and a strong potential for long-term growth and value for investors.

Bears say

Medtronic is facing multiple challenges that make it unlikely the company will see a significant increase in stock price in the near future. Despite having a broad portfolio and several key growth drivers, MDT has consistently underperformed in terms of revenue and earnings growth. In addition, the company's high reliance on government reimbursement programs and potential competitive risks could further hinder its growth and profitability. MDT also faces potential risks related to capital allocation and the performance of its recent M&A activities. Overall, we see limited upside for Medtronic's stock in the current market environment.

Medtronic (MDT) has been analyzed by 20 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 40% recommend Buy, 30% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 20 analysts, Medtronic (MDT) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.